Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05 2022 - 4:30PM
Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS),
a clinical-stage biotechnology company using its pioneering
gene-editing platform to develop life-saving cell and gene
therapies, announced today that pre-clinical data on
TALEN
®-edited smart CAR T-cells to overcome key
challenges of targeting solid tumors, will be presented at the
Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC
2022), to be held in Boston, M.A. and virtually on November 8-12,
2022.
Presentations include:
Poster presentation:
Cellectis will present a poster on TALEN®-edited smart CAR
T-cells targeting MUC1- expressing solid tumors. MUC1 is a
tumor-associated antigen that is overexpressed in triple-negative
breast cancer (TNBC) and other solid tumor malignancies.
Title: Multi-armored allogeneic MUC-1 CAR
T-cells efficiently control triple negative breast cancer tumor
growth Poster Number:
217Presenter: Piril, Erler Ph.D., Scientist II,
Immuno-Oncology, CellectisDate/Time: Thursday,
November 10th, posters will be on display from 9:00 AM- 9:00 PM,
Hall C
Poster presentation:
Cellectis will present a poster on innovative T-cell engineering
strategies designed to increase the activity of CAR T-cells for
solid tumors while mitigating toxicity risk.
Title: TALEN®-edited smart CAR
T-cells leverage solid tumor microenvironment for specific and
effective immunotherapyPoster Number:
325Presenter: Shipra Das Ph.D., Senior Scientist
& Team Leader Immuno-Oncology,
CellectisDate/Time: Thursday, November 10th,
posters will be on display from 9:00 AM- 9:00 PM, Hall C
Full text of the abstracts will be released on the SITC website
at 8:00 a.m. EST on November 7, 2022.
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
22 years of experience and expertise in gene editing, Cellectis is
developing life-changing product candidates utilizing TALEN®, its
gene editing technology, and PulseAgile, its pioneering
electroporation system to harness the power of the immune system in
order to treat diseases with unmet medical needs. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
For more information, visit www.cellectis.com.
Follow Cellectis on social media: @cellectis, LinkedIn and
YouTube.
For further information, please
contact:
Media contacts: Pascalyne
Wilson, Director, Communications, +33 (0)7 76 99 14
33, media@cellectis.com Margaret Gandolfo, Senior Manager,
Communications, +1 (646) 628 0300
Investor Relation contact: Arthur
Stril, Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci
Advisors, +1 617 430 7577
Forward-looking StatementsThis
press release contains “forward-looking” statements within the
meaning of applicable securities laws, including the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as “anticipate,”
“believe,” “intend,” “expect,” “plan,” “scheduled,” “could,” “may”
and “will,” or the negative of these and similar expressions. These
forward-looking statements, which are based on our management’s
current expectations and assumptions and on information currently
available to management. Forward-looking statements include
statements about the potential of our product candidates. These
forward-looking statements are made in light of information
currently available to us and are subject to numerous risks and
uncertainties, including with respect to the numerous risks
associated with biopharmaceutical product candidate development.
With respect to our cash runway, our operating plans, including
product development plans, may change as a result of various
factors, including factors currently unknown to us. Furthermore,
many other important factors, including those described in our
Annual Report on Form 20-F and the financial report (including the
management report) for the year ended December 31, 2021 and
subsequent filings Cellectis makes with the Securities Exchange
Commission from time to time, as well as other known and unknown
risks and uncertainties may adversely affect such forward-looking
statements and cause our actual results, performance or
achievements to be materially different from those expressed or
implied by the forward-looking statements. Except as required by
law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results
could differ materially from those anticipated in the
forward-looking statements, even if new information becomes
available in the future.
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cellectis (NASDAQ:CLLS)
Historical Stock Chart
From Sep 2023 to Sep 2024